← Eichor
Condition: Triple Negative Breast Cancer Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Triple Negative Breast Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer
Phase 4 · 34 location(s) · Fudan University · NCT04790305All Trans Retinoic Acid Combined with Toripalimab+Chemotherapy for Locally Advanced Inoperable or Metastatic Triple Nega
Phase 2 · 2 location(s) · Fudan University · NCT06636981Stereotactic Radiotherapy Combined With Adebrelimab and TCb (Nab-paclitaxel + Carboplatin) in Neoadjuvant Treatment of T
Phase 2 · 1 location(s) · Shengjing Hospital · NCT06165900Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
Phase 1 · 29 location(s) · Novartis Pharmaceuticals · NCT06562192Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breas
Phase 2 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT07394387a Single-arm, Single-center, Open Clinical Study
Phase N/A · 1 location(s) · Beijing Geekgene Technology Co., LTD · NCT06431100NeoCARD: Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer Patients
Phase 2 · 1 location(s) · Medical University of South Carolina · NCT06845319Study of XB010 in Subjects With Solid Tumors
Phase 1 · 20 location(s) · Exelixis · NCT06545331QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer
Phase 2 · 1 location(s) · Affiliated Hospital of Nantong University · NCT07342283Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells
Phase 1 · 1 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT06347068The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors
Phase N/A · 1 location(s) · VastBiome · NCT05037825High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metast
Phase 2 · 1 location(s) · Emory University · NCT06492759A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who H
Phase 3 · 1 location(s) · Jiangsu Alphamab Biopharmaceuticals Co., Ltd · NCT07533123A Study of Pembrolizumab and Cryoablation in People With Breast Cancer
Phase 1 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT06246968Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Phase 1/Phase 2 · 13 location(s) · Exscientia AI Ltd., a wholly owned subsidiary of Recursion P · NCT05985655First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
Phase 1/Phase 2 · 16 location(s) · Tubulis GmbH · NCT06657222Prevention of Sacituzumab Govitecan-related Neutropenia in Patients With Metastatic Triple Negative Breast Cancer
Phase 2 · 1 location(s) · Yeon Hee Park · NCT06616987Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer
Phase 2 · 1 location(s) · Mayo Clinic · NCT06635980Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors
Phase 1 · 1 location(s) · Novartis Pharmaceuticals · NCT07630961A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative
Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT04683679Telemonitoring Platform "CUREETY TECHCARE" vs Standard of Care for mTBNC Patients Initiating a First-line Treatment
NA · 51 location(s) · UNICANCER · NCT06505018Trilaciclib Combined With Anti-PD-1 Antibody and Chemotherapy in the Treatment of Locally Advanced TNBC
Phase 2 · 1 location(s) · QIAO LI · NCT06955156Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK
Phase 2 · 9 location(s) · Swiss Cancer Institute · NCT06358573Immunotherapy-related CRP Kinetics in Early and Metastatic Triple-negative Breast Cancer
Phase N/A · 1 location(s) · University Hospital Tuebingen · NCT05914961Real-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA Inhibitors,
Phase N/A · 1 location(s) · Hunan Cancer Hospital · NCT07073755Atezolizumab and Chemotherapy Treatment as T-cell Activators in Metastatic Triple Negative Breast Cancer Patients
Phase 2 · 5 location(s) · European Institute of Oncology · NCT06690840This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Tor
Phase 1 · 3 location(s) · Zumutor Biologics Inc. · NCT06451497Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery
Phase 2 · 20 location(s) · UNICANCER · NCT05973864A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer
Phase 3 · 2 location(s) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. · NCT07111832Pembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast Cancer
Phase 2 · 14 location(s) · Yukinori Ozaki · NCT06976944
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.